Literature DB >> 22504780

Successful treatment of HER-2-positive metastatic apocrine carcinoma of the skin with lapatinib and capecitabine.

Takanori Hidaka, Taku Fujimura, Akiko Watabe, Akira Hashimoto, Takahiro Haga, Kaoru Onami, Masato Mizuashi, Setsuya Aiba.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22504780     DOI: 10.2340/00015555-1354

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   4.437


× No keyword cloud information.
  5 in total

1.  Apocrine-eccrine carcinomas: molecular and immunohistochemical analyses.

Authors:  Long P Le; Dora Dias-Santagata; Amanda C Pawlak; Arjola K Cosper; Anh Thu Nguyen; M Angelica Selim; April Deng; Nora K Horick; A John Iafrate; Martin C Mihm; Mai P Hoang
Journal:  PLoS One       Date:  2012-10-09       Impact factor: 3.240

2.  Successful Treatment of Advanced Primary Cutaneous Apocrine Carcinoma on the Scrotum with Systemic Chemotherapy and Radiotherapy Followed by Denosumab.

Authors:  Sadanori Furudate; Taku Fujimura; Akira Tsukada; Yota Sato; Takanori Hidaka; Kayo Tanita; Yumi Kambayashi; Takahiro Haga; Akira Hashimoto; Setsuya Aiba
Journal:  Case Rep Oncol       Date:  2017-01-16

3.  Treatment of Malignant Adnexal Tumors of the Skin: A 12-Year Perspective.

Authors:  Marcin Kleibert; Iga Płachta; Anna M Czarnecka; Mateusz J Spałek; Anna Szumera-Ciećkiewicz; Piotr Rutkowski
Journal:  Cancers (Basel)       Date:  2022-02-16       Impact factor: 6.639

Review 4.  Primary cutaneous apocrine carcinoma of the scalp: Two case reports and literature review.

Authors:  Jun Ho Choi; Hyun Myung Oh; Kwang Seog Kim; Yoo Duk Choi; Sung Pil Joo; Won Joo Hwang; Jae Ha Hwang; Sam Yong Lee
Journal:  Medicine (Baltimore)       Date:  2022-02-11       Impact factor: 1.817

Review 5.  Current Diagnosis and Treatment Options for Cutaneous Adnexal Neoplasms with Apocrine and Eccrine Differentiation.

Authors:  Iga Płachta; Marcin Kleibert; Anna M Czarnecka; Mateusz Spałek; Anna Szumera-Ciećkiewicz; Piotr Rutkowski
Journal:  Int J Mol Sci       Date:  2021-05-11       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.